Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1173-1178

  Rogóz, Zofia ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Desipramine; Forced swimming test; Metyrapone; Rats; Reboxetine

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; DESIPRAMINE; METYRAPONE; N [2 [4 (2 METHOXYOPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDINYL) CYCLOHEXANECARBOXAMIDE TRIHYDROCHLORIDE; PRAZOSIN; REBOXETINE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; WAY 10635;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL MODEL; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOLECULAR MECHANICS; NONHUMAN; OPEN FIELD TEST; RAT;

EID: 76049123724     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70180-X     Document Type: Article

References (30)

1. Baez M, Volosin M: Corticosterone influences forced swim-induced immobility. Pharmacol Biochem Behav, 1994, 49, 729-736.
2. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord, 2001, 64, 261-265.
3. 1A receptor mRNA expression. Trends Neurosci, 1993, 13, 914-923.
4. 1A receptor antagonist, WAY 100635. Eur J Pharmacol, 1995, 281, 81-88.
5. 1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berl), 1987, 91, 500-505.
6. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE: Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl), 1999, 145, 203-208.
7. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry, 1996, 153, 93-99.
8. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
9. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev, 1996, 17, 187-205.
10. Holsboer F, Gerken A, Stalla GK, Muller O: ACTH, cortisol and corticosterone output after ovine corticotrophinreleasing factor challenge during depression and after recovery. Biol Psychiatry, 1985, 20, 276-286.
11. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridias A, Wiedemann K: Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry, 2004, 61, 1235-1244.
12. Janssen PAJ, Jageneau AHM, Schellekens KHL: Chemistry and pharmacology of compounds releated to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. Part IV. Influence of haloperidol (R 1625) or chloropromazine on the behaviour of rats in unfamiliar "open field" situation. Psychopharmacologia, 1960, 1, 389-392.
13. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med, 1979, 48, 465-472.
14. Kennett GA, Dickinson SL, Curzon G: Central serotonergic responses and behavioral adaptation to repeated immobilization: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol, 1985, 119, 143-152.
15. Korstein SG, Schneider RK: Clinical features of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
16. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Goldstein J, Copinschi G, Van Cauter E: The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab, 1985, 61, 429-438.
17. A receptor. Mechanism of action and physiological significance. Prog Neurobiol, 1992, 38, 379-395.
18. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoendocrinology, 1997, 22, Suppl 1, S125-S132.
19. Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD et al.: Elevated concentrations of CRF corticotropin releasing factor-like immunoreactivity in depressed patients. Science, 1984, 226, 1342-1344.
20. O'Brien D, Skelton KH, Owens MJ, Nemeroff CB: Are CRF receptor antagonists potential antidepressants? Hum Psychopharmacol, 2001, 16, 81-87.
21. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry, 2001, 49, 391-404.
22. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats, a new model sensitive to antidepressant treatment. Eur J Pharmacol, 1978, 47, 379-391.
23. Price LH, Malison RT, McDougle CJ, Pelton GH: Antiglucocorticoids as treatments for depression. Rationale for use and therapeutic potential. CNS Drugs, 1996, 5, 311-320.
24. Raven PW, O'Dwyer A-M, Taylor NF, Checkley SA: The relationship between the effect of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology, 1996, 21, 277-286.
25. 1-adrenergic system in rats. Pharmacol Rep, 2007, 59, 588-594.
26. Rogóż Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W: Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitaryadrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol, 2005, 56, 49-61.
27. Rogóż Z, Skuza G, Leśkiewicz M, Budziszewska B: Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep, 2008, 60, 880-888.
28. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA: Effect of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol, 2003, 55, 993-999.
29. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA, Wróbel A, Dudek D, Ziȩba A: Effect of metyrapone supplementation on imipramine therapy in patients with treatmentresistant unipolar depression. Pol J Pharmacol, 2004, 56, 849-855.
30. Roozendaal B, Bohus B, McGaugh JL: Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotional and memory. Psychoendocrinology, 1996, 21, 681-693.